RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Innovent Biologics of Suzhou reported strong preliminary results from a China Phase II trial of its PD-1 candidate, sintilimab (IBI308). In 96 patients with relapsed/refractory classical Hodgkin Lymphoma, sintilimab produced an overall response rate of 79% and a disease control rate of 98%, meeting the endpoints of the study. Innovent said it submitted an NDA to the CFDA for sintilimab on April 19, 2018, which will be reviewed following speeded-up Priority Review rules.
Source: China Biotoday